Martin Schönlein

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment

C. Bokemeyer, M. Sinn, J. Schulze zur Wiesch, 2021, Cancers.

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

M. Kudo, P. Galle, N. Nishida, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

L. Pagano, F. Farina, M. Hoenigl, 2022, American journal of hematology.

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

A. Barać, L. Pagano, B. Drénou, 2021, Journal of Hematology & Oncology.

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Yuehua Wu, M. Kudo, P. Galle, 2022, Cancers.

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

Victor G. Puelles, T. Renné, C. Bokemeyer, 2023, Nature.

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

M. Kudo, P. Galle, N. Nishida, 2022, Hepatology.

Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

A. Barać, Gina Varricchio, G. Nadali, 2024, EClinicalMedicine.